Lv1
90 积分 2020-11-18 加入
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies
9天前
已完结
Comparison of protein-based and genetic prognostic markers in a large cohort of primary pulmonary and extrapulmonary small cell neuroendocrine carcinoma
13天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
13天前
已完结
Cross-priming underlies the efficacy of antibody-drug conjugates and immunotherapy combinations
23天前
已完结
Immunology: Breast Cancer
23天前
已关闭
Two decades of PARP inhibitor synthetic lethality in cancer
1个月前
已完结
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
1个月前
已完结
Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guideline
2个月前
已完结
Trastuzumab Deruxtecan Resistance via Loss of HER2 Expression and Binding
3个月前
已完结
The SDC1-ENO1 Axis in Cancer-Associated Fibroblasts Generates a Lactate-Rich Microenvironment that Drives Tumor Radioresistance
4个月前
已完结
皖公网安备34019202002308
